{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:47:09Z","timestamp":1790923629867,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40273-025-01542-8","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T11:51:02Z","timestamp":1758714662000},"page":"25-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Eladocagene Exuparvovec for the Treatment of Aromatic l-Amino Acid Decarboxylase Deficiency (AADCd): An Economic Evaluation from a US Perspective"],"prefix":"10.1007","volume":"44","author":[{"given":"Rongrong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berrin","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixi","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-4583","authenticated-orcid":false,"given":"Ioannis","family":"Tomazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"1542_CR1","doi-asserted-by":"crossref","unstructured":"Palma JA, Norcliffe-Kaufmann L, Fuente-Mora C, Percival L, Spalink CL, Kaufmann H. 154-Disorders of the autonomic nervous system: autonomic dysfunction in pediatric practice. In: Swaiman KF, Ashwal S, Ferriero DM, Schor NF, Finkel RS, Gropman AL, Pearl PL. Swaiman\u2019s pediatric neurology, editors. 6th ed. Elsevier. 2017:1173-83.","DOI":"10.1016\/B978-0-323-37101-8.00154-5"},{"issue":"5","key":"1542_CR2","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/s41390-023-02685-0","volume":"94","author":"JE Park","year":"2023","unstructured":"Park JE, Lee T, Ha K, Cho EH, Ki CS. Carrier frequency and incidence of aromatic L-amino acid decarboxylase deficiency: a gnomad-based study. Pediatr Res. 2023;94(5):1764\u201370. https:\/\/doi.org\/10.1038\/s41390-023-02685-0.","journal-title":"Pediatr Res"},{"issue":"4","key":"1542_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2016.05.011","volume":"118","author":"YH Chien","year":"2016","unstructured":"Chien YH, Chen PW, Lee NC, et al. 3-O-methyldopa levels in newborns: result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Mol Genet Metab. 2016;118(4):259\u201363. https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.011.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"1542_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13023-016-0522-z","volume":"12","author":"T Wassenberg","year":"2017","unstructured":"Wassenberg T, Molero-Luis M, Jeltsch K, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12(1):12. https:\/\/doi.org\/10.1186\/s13023-016-0522-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1542_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jimd.12247","volume":"43","author":"TS Pearson","year":"2020","unstructured":"Pearson TS, Gilbert L, Opladen T, et al. AADC deficiency from infancy to adulthood: symptoms and developmental outcome in an international cohort of 63 patients. J Inherit Metab Dis. 2020;43(5):1121\u201330. https:\/\/doi.org\/10.1002\/jimd.12247.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1542_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13052-021-00954-4","volume":"47","author":"C Fusco","year":"2021","unstructured":"Fusco C, Leuzzi V, Striano P, et al. Aromatic l-amino acid decarboxylase (AADC) deficiency: results from an Italian modified Delphi consensus. Ital J Pediatr. 2021;47(1):13. https:\/\/doi.org\/10.1186\/s13052-021-00954-4.","journal-title":"Ital J Pediatr"},{"issue":"1","key":"1542_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-022-02274-0","volume":"17","author":"K Williams","year":"2022","unstructured":"Williams K, Skrobanski H, Buesch K, Acaster S. Symptoms and impacts of aromatic l-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function. Orphanet J Rare Dis. 2022;17(1):128. https:\/\/doi.org\/10.1186\/s13023-022-02274-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"1542_CR8","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1080\/03007995.2022.2072090","volume":"38","author":"K Buesch","year":"2022","unstructured":"Buesch K, Rongrong Z, Katarzyna S, et al. Burden and severity of disease of aromatic L-amino acid decarboxylase deficiency: a systematic literature review. Curr Med Res Opin. 2022;38(11):1871\u201382. https:\/\/doi.org\/10.1080\/03007995.2022.2072090.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1542_CR9","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1080\/03007995.2021.1955668","volume":"37","author":"H Skrobanski","year":"2021","unstructured":"Skrobanski H, Williams K, Werner C, O\u2019Neill S, Buesch K, Acaster S. The impact of caring for an individual with aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a conceptual model. Curr Med Res Opin. 2021;37(10):1821\u20138. https:\/\/doi.org\/10.1080\/03007995.2021.1955668.","journal-title":"Curr Med Res Opin"},{"key":"1542_CR10","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1016\/j.jval.2021.04.1036","volume":"24","author":"K Buesch","year":"2021","unstructured":"Buesch K, Williams K, Skrobanski H, Acaster S. PRO51 caring for an individual with aromatic L-amino acid decarboxylase (AADC) deficiency: analysis of reported time for practical and emotional care and paid\/unpaid help. Value Health. 2021;24:S206. https:\/\/doi.org\/10.1016\/j.jval.2021.04.1036.","journal-title":"Value Health"},{"issue":"1","key":"1542_CR11","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","volume":"12","author":"TS Pearson","year":"2021","unstructured":"Pearson TS, Gupta N, San Sebastian W, et al. Gene therapy for aromatic l-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. Nat Commun. 2021;12(1):4251. https:\/\/doi.org\/10.1038\/s41467-021-24524-8.","journal-title":"Nat Commun"},{"issue":"4","key":"1542_CR12","doi-asserted-by":"publisher","DOI":"10.2217\/fnl-2022-0012","volume":"17","author":"M Bergkvist","year":"2022","unstructured":"Bergkvist M, Stephens C, Schilling T, et al. Aromatic l-amino acid decarboxylase deficiency: a systematic review. Future Neurol. 2022;17(4):FNL63. https:\/\/doi.org\/10.2217\/fnl-2022-0012.","journal-title":"Future Neurol"},{"issue":"1","key":"1542_CR13","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/j.jval.2021.11.474","volume":"25","author":"F Fern\u00e1ndez-Cort\u00e9s","year":"2022","unstructured":"Fern\u00e1ndez-Cort\u00e9s F, Saberian S, Patel P, Rowan P, Buesch K, Beitia Ortiz de Zarate I. POSC69 healthcare resource consumption associated with aromatic l-amino acid decarboxylase deficiency (AADC-D) in Italy. Value Health. 2022;25(1):S99\u2013100. https:\/\/doi.org\/10.1016\/j.jval.2021.11.474.","journal-title":"Value Health."},{"key":"1542_CR14","doi-asserted-by":"publisher","first-page":"S202","DOI":"10.1016\/j.jval.2021.04.1013","volume":"24","author":"C Le Dissez","year":"2021","unstructured":"Le Dissez C, Jocelyn D, Hammes F, Buesch K, Maurel F, Beitia Ortiz de Zarate I. PRO28 healthcare resource use (HCRU) of patients with aromatic l-amino acid decarboxylase deficiency (AADC-D) in France. Value Health. 2021;24:S202. https:\/\/doi.org\/10.1016\/j.jval.2021.04.1013.","journal-title":"Value Health."},{"key":"1542_CR15","unstructured":"U.S. Food & Drug Administration. FDA approves first gene therapy for treatment of aromatic L-amino Acid decarboxylase deficiency 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-aromatic-l-amino-acid-decarboxylase-deficiency. Accessed 22 Sep 2025."},{"key":"1542_CR16","unstructured":"PTC Therapeutics Inc. Kebilidi Prescribing Information 2024 [Available from: https:\/\/www.ptcbio.com\/wp-content\/uploads\/sites\/2\/2024\/11\/Kebilidi-Prescribing-Information.pdf. Accessed 22 Sep 2025."},{"issue":"4","key":"1542_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","volume":"1","author":"Y-H Chien","year":"2017","unstructured":"Chien Y-H, Lee N-C, Tseng S-H, et al. Efficacy and safety of AAV2 gene therapy in children with aromatic l-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial. Lancet Child Adolesc Health. 2017;1(4):265\u201373. https:\/\/doi.org\/10.1016\/S2352-4642(17)30125-6.","journal-title":"Lancet Child Adolesc Health"},{"issue":"134","key":"1542_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003640","volume":"4","author":"WL Hwu","year":"2012","unstructured":"Hwu WL, Muramatsu S, Tseng SH, et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med. 2012;4(134):134ra61. https:\/\/doi.org\/10.1126\/scitranslmed.3003640.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1542_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","volume":"30","author":"CH Tai","year":"2022","unstructured":"Tai CH, Lee NC, Chien YH, et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther J Am Soc Gene Ther. 2022;30(2):509\u201318. https:\/\/doi.org\/10.1016\/j.ymthe.2021.11.005.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"1542_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-025-03584-9","volume":"20","author":"W-L Hwu","year":"2025","unstructured":"Hwu W-L, Lee H-M, Peipert JD, et al. Clinically meaningful improvements after gene therapy for aromatic l-amino acid decarboxylase deficiency (AADCd) in the Peabody developmental motor scale, second edition (PDMS-2) and correlation with Bayley-III scores and motor milestones. Orphanet J Rare Dis. 2025;20:58. https:\/\/doi.org\/10.1186\/s13023-025-03584-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1542_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12955-025-02335-5","volume":"23","author":"B Monteleone","year":"2025","unstructured":"Monteleone B, Forster K, Chua GN, et al. Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States. Health Qual Life Outcomes. 2025;23(1):7. https:\/\/doi.org\/10.1186\/s12955-025-02335-5.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"1542_CR22","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1007\/s12325-023-02689-6","volume":"40","author":"CL Simons","year":"2023","unstructured":"Simons CL, Hwu W-L, Zhang R, Simons MJHG, Bergkvist M, Bennison C. Long-term outcomes of eladocagene exuparvovec compared with standard of care in aromatic l-amino acid decarboxylase (AADC) deficiency: a modelling study. Adv Ther. 2023;40(12):5399\u2013414. https:\/\/doi.org\/10.1007\/s12325-023-02689-6.","journal-title":"Adv Ther"},{"issue":"12","key":"1542_CR23","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1016\/j.jval.2024.10.935","volume":"27","author":"B Monteleone","year":"2024","unstructured":"Monteleone B, Zhang R, Castellano P, Oconnell T, Teng Y, Tomazos I. EE655 cost-effectiveness analysis of Eladocagene exuparvovec for the treatment of aromatic L-amino acid decarboxylase deficiency (AADCd) from a United States (US) perspective. Value Health. 2024;27(12):S184. https:\/\/doi.org\/10.1016\/j.jval.2024.10.935.","journal-title":"Value Health"},{"issue":"1","key":"1542_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03584-9","volume":"20","author":"W-L Hwu","year":"2025","unstructured":"Hwu W-L, Lee H-M, Peipert JD, et al. Clinically meaningful improvements after gene therapy for aromatic L-amino acid decarboxylase deficiency (AADCd) in the Peabody developmental motor scale, second edition (PDMS-2) and correlation with Bayley-III scores and motor milestones. Orphanet J Rare Dis. 2025;20(1):58. https:\/\/doi.org\/10.1186\/s13023-025-03584-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"1542_CR25","first-page":"1","volume":"72","author":"E Arias","year":"2023","unstructured":"Arias E, Xu J, Kochanek K. United States life tables, 2021. Natl Vital Stat Rep. 2023;72(12):1\u201364.","journal-title":"Natl Vital Stat Rep"},{"issue":"11","key":"1542_CR26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/dmcn.12519","volume":"56","author":"JC Brooks","year":"2014","unstructured":"Brooks JC, Strauss DJ, Shavelle RM, Tran LM, Rosenbloom L, Wu YW. Recent trends in cerebral palsy survival. Part II: individual survival prognosis. Dev Med Child Neurol. 2014;56(11):1065\u201371. https:\/\/doi.org\/10.1111\/dmcn.12519.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1542_CR27","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.jval.2021.11.369","volume":"25","author":"L Sope\u00f1a","year":"2022","unstructured":"Sope\u00f1a L, Simons C, Mumford A, et al. POSB96 economic model for a gene therapy in an ultra-rare disease: expert validation of approach and assumptions. Value Health. 2022;25(1):S79. https:\/\/doi.org\/10.1016\/j.jval.2021.11.369.","journal-title":"Value Health"},{"issue":"6","key":"1542_CR28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989x11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Mak. 2011;31(6):800\u20134. https:\/\/doi.org\/10.1177\/0272989x11401031.","journal-title":"Med Decis Mak"},{"key":"1542_CR29","unstructured":"Optum360. DRG Expert 2021. https:\/\/www.optumcoding.com\/product\/49260\/. Accessed 22 Sep 2025."},{"issue":"7","key":"1542_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/03007995.2022.2078097","volume":"38","author":"S Saberian","year":"2022","unstructured":"Saberian S, Rowan P, Hammes F, et al. Burden of illness of aromatic l-amino acid decarboxylase deficiency: a survey of physicians in Southern Europe. Curr Med Res Opin. 2022;38(7):1115\u201323. https:\/\/doi.org\/10.1080\/03007995.2022.2078097.","journal-title":"Curr Med Res Opin"},{"key":"1542_CR31","unstructured":"Centers for Medicare & Medicaid Services. List of CPT\/HCPCS Codes. 2024 annual update to the code list. https:\/\/www.cms.gov\/medicare\/regulations-guidance\/physician-self-referral\/list-cpt-hcpcs-codes. Accessed 22 Sep 2025."},{"key":"1542_CR32","unstructured":"Merative. Micromedex RED BOOK 2024. https:\/\/www.merative.com\/documents\/micromedex-red-book. Accessed 22 Sep 2025."},{"issue":"5","key":"1542_CR33","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s00415-016-8080-9","volume":"263","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Lindgren P, Bell CF, et al. Quantifying the burden of caregiving in Duchenne muscular dystrophy. J Neurol. 2016;263(5):906\u201315. https:\/\/doi.org\/10.1007\/s00415-016-8080-9.","journal-title":"J Neurol"},{"key":"1542_CR34","unstructured":"National Institute of Health and Care Excellence. Risdiplam for treating spinal muscular atrophy in children and adults [ID1631] 2021. https:\/\/www.nice.org.uk\/guidance\/ta755\/documents\/committee-papers-3. Accessed 22 Sep 2025."},{"issue":"3","key":"1542_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1741-3729.2010.00601.x","volume":"59","author":"J Song","year":"2010","unstructured":"Song J, Floyd FJ, Seltzer MM, Greenberg JS, Hong J. Long-term effects of child death on parents\u2019 health related quality of life: a dyadic analysis. Fam Relat. 2010;59(3):269\u201382. https:\/\/doi.org\/10.1111\/j.1741-3729.2010.00601.x.","journal-title":"Fam Relat"},{"key":"1542_CR36","unstructured":"Folio MR, Fewell RR. Peabody Developmental Motor Scales-2 Austin, TX; 2000."},{"key":"1542_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.earlhumdev.2019.04.005","volume":"132","author":"SLC Veldman","year":"2019","unstructured":"Veldman SLC, Santos R, Jones RA, Sousa-S\u00e1 E, Okely AD. Associations between gross motor skills and cognitive development in toddlers. Early Hum Dev. 2019;132:39\u201344. https:\/\/doi.org\/10.1016\/j.earlhumdev.2019.04.005.","journal-title":"Early Hum Dev"},{"issue":"4","key":"1542_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/PEP.0b013e318267c5cf","volume":"24","author":"BH Connolly","year":"2012","unstructured":"Connolly BH, McClune NO, Gatlin R. Concurrent validity of the Bayley-III and the Peabody developmental motor scale-2. Pediatr Phys Ther. 2012;24(4):345\u201352. https:\/\/doi.org\/10.1097\/PEP.0b013e318267c5cf.","journal-title":"Pediatr Phys Ther"},{"issue":"3","key":"1542_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/01.Pep.0000136005.41585.Fe","volume":"16","author":"B Provost","year":"2004","unstructured":"Provost B, Heimerl S, McClain C, Kim NH, Lopez BR, Kodituwakku P. Concurrent validity of the Bayley scales of infant development II motor scale and the Peabody developmental motor scales-2 in children with developmental delays. Pediatr Phys Ther. 2004;16(3):149\u201356. https:\/\/doi.org\/10.1097\/01.Pep.0000136005.41585.Fe.","journal-title":"Pediatr Phys Ther"},{"key":"1542_CR40","unstructured":"European Medicines Agency. Upstaza: EPAR- Product Information The Netherlands: European Medicines Agency; 2024 . https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/upstaza-epar-product-information_en.pdf. Accessed 22 Sep 2025."},{"key":"1542_CR41","unstructured":"National Institute for Health and Care Excellence. Eladocagene exuparvovec for treating aromatic Lamino acid decarboxylase deficiency (HST26) 2023. https:\/\/www.nice.org.uk\/guidance\/hst26\/resources\/eladocagene-exuparvovec-for-treating-aromatic-lamino-acid-decarboxylase-deficiency-pdf-50216322673861. Accessed 22 Sep 2025."},{"issue":"6","key":"1542_CR42","doi-asserted-by":"publisher","first-page":"S345","DOI":"10.1016\/j.jval.2023.03.1952","volume":"26","author":"SH Lo","year":"2023","unstructured":"Lo SH, Chang SC, Acaster S. PCR176 estimating utility values for health states in metachromatic leukodystrophy (MLD). Value Health. 2023;26(6):S345. https:\/\/doi.org\/10.1016\/j.jval.2023.03.1952.","journal-title":"Value Health"},{"issue":"4","key":"1542_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","volume":"7","author":"JL Severens","year":"2004","unstructured":"Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health. 2004;7(4):397\u2013401. https:\/\/doi.org\/10.1111\/j.1524-4733.2004.74002.x.","journal-title":"Value Health"},{"key":"1542_CR44","unstructured":"Institute for Clinical Economic Review. Spinraza and Zolgensma for spinal muscular atrophy: effectiveness and value. Final evidence report 2019 [Available from: https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_052419.pdf&ved=2ahUKEwj0gtj19uyPAxXPIzQIHYVvIwYQFnoECAsQAQ&usg=AOvVaw0xLp5c8fClRmB19jPACCcB"},{"key":"1542_CR45","unstructured":"Institute for Clinical and Economic Review. Atidarsagene autotemcel for metachromatic leukodystrophy\u2014final evidence report. October 30, 2023. https:\/\/icer.org\/wp-content\/uploads\/2023\/10\/MLD-Final-Evidence-Report_For-Publication_10302023.pdf. Accessed 22 Sep 2025."},{"key":"1542_CR46","unstructured":"Fierce Pharma. BioMarin's hemophilia gene therapy Roctavian lands FDA nod with 'glimmers' of enthusiasm among doctors [Jun 29, 2023]. https:\/\/www.fiercepharma.com\/pharma\/biomarins-hemophilia-gene-therapy-roctavian-lands-fda-nod-glimmers-enthusiasm-among-doctors. Accessed 22 Sep 2025."},{"issue":"1","key":"1542_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s13023-024-03382-9","volume":"19","author":"A Looby","year":"2024","unstructured":"Looby A, Dymond A, Green W, Wentzel H, Malottki K. Uncertainties in evaluating the health-related quality of life and disease burden of people with rare diseases and their caregivers in NICE HST submissions. Orphanet J Rare Dis. 2024;19(1):391. https:\/\/doi.org\/10.1186\/s13023-024-03382-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1542_CR48","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA"},{"key":"1542_CR49","unstructured":"National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013 London: National Institute for Health and Care Excellence,; 2013 [Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword."},{"issue":"10","key":"1542_CR50","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jval.2020.05.017","volume":"23","author":"BM Pennington","year":"2020","unstructured":"Pennington BM. Inclusion of carer health-related quality of life in National Institute for Health and Care Excellence appraisals. Value Health. 2020;23(10):1349\u201357. https:\/\/doi.org\/10.1016\/j.jval.2020.05.017.","journal-title":"Value Health"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01542-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01542-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01542-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:54:04Z","timestamp":1768366444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01542-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1542"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01542-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RZ, PC, and IT are employees of PTC Therapeutics Inc. and may be shareholders in the company. TOC and YT are employees of Medicus Economics which was contracted by PTC Therapeutics Inc. for the conduct of this study. PW-HL and BM received consulting fees from PTC Therapeutics Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets produced during this study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study used de-identified secondary data, and therefore did not require ethical approval or individual patient consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors contributed to the study conception and design. Data analysis was performed by YT and TOC. All authors contributed to the writing of the manuscript. All authors read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"As the data used in this study were anonymized, participant consent to participate was not necessary.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"As the data used in this study were anonymized, participant consent for publication was not necessary.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}